drugset / Trial / NCT00770445

Efficacy of Pioglitazone and Metformin on Cardiovascular Risk in Subjects With Insulin-Treated Type 2 Diabetes Mellitus.

NCT00770445

Phase 4 Completed 121 enrolled Takeda
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine the Anti-Inflammation Effects of Pioglitazone, twice daily (BID), and Pioglitazone/Metformin Combination Therapy BID in Type 2 Diabetes Subjects Treated with Insulin.

Timeline

Start
2008-05
Primary completion
2010-07
Completion
2010-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Metformin Small molecule 850 mg Oral
Subject Pioglitazone Small molecule 15 mg Oral
Background insulin glargine Protein / enzyme biologic

Indications